China Food and Drug Administration has approved Pfizer China to begin marketing Xeljanz, a drug for treating moderate to severe rheumatoid arthritis.
"We applaud the efforts of Chinese Government and the CFDA to bring new medicines to the Chinese healthcare system," Dr. Wu Xiaobin, country manager of Pfizer China, said in a press release. "Pfizer is committed to working closely with the CFDA, and will continue to partner with the Chinese government with the goal to help improve the lives of patients and people in China."
The recommended dose of Xeljanz is 5 milligrams taken twice daily, orally with or without food. Since it was first approved in the United States in 2012, more than 90,000 patients worldwide have taken the drug, according to the release.
